Branded drug firms settling more patent suits: WSJ

Share this article:
Emboldened by fewer antitrust challenges, branded pharmaceutical companies are more often choosing to settle patent litigation with generic drug makers, The Wall Street Journal reports. The settlements pose an alternative to long and risky court proceedings, which can harm share price, but they don’t come cheap. Branded firms must agree to shorten the patent life of the drug, foregoing millions in potential revenue. Cephalon recently settled with three of the four generic makers challenging the patent on its sleep-disorder drug Provigil, giving up three years of patent exclusivity in the deal. Other firms, such as Wyeth and Johnson & Johnson, have settled patent disputes over important drugs. Analysts expect more, including settlements involving Forest Labs’ antidepressant Lexapro and J&J’s ADHD drug Adderall XR. Though the Federal Trade Commission (FTC) aggressively pursues such cases because they could delay competition and hurt consumers, recent state- and federal-court judges have ruled that settlements are not by definition anticompetitive. This has made industry executives more confident of surviving regulatory challenges, according to the Journal report. The settlements are a mixed blessing for consumers and insurers but may be a boon for pharma companies. An FTC study found generic makers won almost 75% of patent litigation suits.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.